The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Uveal melanoma: Real-world analysis of immune checkpoint inhibitors efficacy and lymphocyte-to-monocyte ratio as a biomarker of response.
 
Antoine Desilets
No Relationships to Disclose
 
Chloe Beland
No Relationships to Disclose
 
Valerie Hladky
No Relationships to Disclose
 
Steph A. Pang
No Relationships to Disclose
 
Arielle Elkrief
Other Relationship - Canadian Institutes of Health Research (CIHR); Cedars Cancer Center; Royal College of Surgeons and Physicians of Canada
 
Andreea Stepanov
No Relationships to Disclose
 
Bertrand Routy
Honoraria - AstraZeneca Canada; Bayer; Bristol-Myers Squibb; Illumina; Pfizer; Vedanta Biosciences
Consulting or Advisory Role - AstraZeneca Canada; Bayer; Bristol-Myers Squibb; Illumina; Pfizer; Vedanta Biosciences
Research Funding - AstraZeneca Canada (Inst); Da Volterra (Inst); Imagia (Inst); Merck (Inst); Vedanta Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - EverImmune
 
Karl Belanger
No Relationships to Disclose
 
Wilson H. Miller
Honoraria - Amgen; Bristol Myers Squibb Foundation; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche; Sanofi; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche; Sanofi
Research Funding - Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Canada Research Society (Inst); Canadian Cancer Society Research Institute (CCSRI) (Inst); Canadian Institutes of Health Research (CIHR) (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); MethylGene (Inst); Mimic Technologies (Inst); Novartis (Inst); Ocellaris Pharma (Inst); Pfizer (Inst); Roche (Inst); Samuel Waxman Cancer Research Foundation (Inst); Sanofi (Inst); TERRY FOX RESEARCH INSTITUTE (Inst)
 
Olivier Larochelle
No Relationships to Disclose
 
Rahima Jamal
Research Funding - Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst)